

MYOS Corp  
Form 8-K  
June 18, 2012

---

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): June 18, 2012 (June 14, 2012)

MYOS CORPORATION  
(Exact name of registrant as specified in its charter)

Nevada (State or other jurisdiction of incorporation)	000-53298 (Commission File Number)	20-8758875 (IRS Employer Identification No.)
--	--	--

45 Horsehill Road, Suite 106  
Cedar Knolls, New Jersey 07927  
(Address of Principal Executive Offices)

(973) 509-0444  
(Issuer's telephone number)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation to the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;  
5.02. Compensatory Arrangements of Certain Officers.

On June 14, 2012, Dr. Carlon Colker resigned from his positions as Chief Medical Officer and Executive Vice President of MYOS Corporation (the “Company”). Simultaneously with such resignation, Dr. Colker agreed to serve on the Company’s Medical Advisory Board, which advises the Company on health issues, medical conditions and health care trends as they relate to the Company’s current and future products. In connection with his appointment to the Medical Advisory Board, Dr. Colker entered into an advisory board agreement with the Company (the “Agreement”), pursuant to which the Company will issue him 300,000 shares of common stock. The Agreement also includes standard confidentiality and non-competition obligations and provisions for intellectual property assignments by Dr. Colker.

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: June 18, 2012

ATLAS THERAPEUTICS CORPORATION

By: /s/ Peter Levy  
Name: Peter Levy  
Title: Chief Operating Officer